Scientists from the University of North Carolina Lineberger Comprehensive Cancer Center have discovered a probable remedial target for kidney cancers with the same genetic alteration. It is well-known fact to scientists that this change in the genetic patterns can result in a plethora of blood vessels, which form a channel for nutrients to reach the tumors.
The FDA held up Mersana’s top antibody-drug conjugate (ADC), XMT-1522 over safety issues following a patient’s death in phase 1 trial, causing a descent in the company’s shares.
Stanford University School of Medicine Researchers have developed a magnetic wire that catches tumor cells flowing in the bloodstream. The wire, inserted into a vein, captures even limited tumor cells, ushering in a new means to detect cancer early.
The first-ever 3D, color X-rays were tested on a human by New Zealand Scientists, using technology that promises to enhance medical diagnostics in oncology, cardiology, neurology and orthopedics.
University of Adelaide researchers have designed a new molecule which targets a protein essential to the growth of most cancers. The protein target is called proliferating cell nuclear antigen (PCNA), also known as the human sliding clamp.
HCC or hepatocellular carcinoma can result in patients getting liver diseases such as viral hepatitis and non-alcoholic fatty liver disease with cirrhosis due to disease progression. New data from recent researches shows factors that improve early detection and diagnosis, and risks prior to HCC and during treatment.
A new technique allows scientists to measure how efficiently cancer drugs reach their targets inside the body in real time, differentiating cells that interact with the drug from those which do not.
A study report published in Nature's Digital Medicine partner journal shows that the wearable monitor Fitbit Charge HR could assess the health condition of cancer patients and predict their adverse events.
The newly formed health insurance administration in China intend to deepen discounts on cancer drugs which were already on its National Reimbursement Drug List (NRDL) based on public bidding and procurement based on cancer therapies. In the meantime, officials will start enlisting negotiations for treatments which were not included on the coverage list.
This app uses a smartphone camera, computer vision algorithms and machine learning tools to assess bilirubin levels in the white part of the eye named sclera since jaundice is considered as one of the earliest symptoms of pancreatic cancer. The eyes and the skin become yellow colored due to the accumulation of bilirubin in the blood caused by jaundice.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.